Relugolix (Orgovyx®)

Clinical Indication

For treating hormone sensitive prostate cancer

Comments

Restricted to patients who would otherwise have been prescribed Degarelix.

In line with TA995

 

Date of classification

November 2024

Yellow

Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .